24.11.2014 • NewsValeantAllerganActavis

Valeant Slashes Stake in Allergan After Losing Bid

Valeant Pharmaceuticals International has cut its stake in US drugmaker Allergan to 0.1%, making the sale three days after Actavis trumped its offer for the Botox maker.

In a regulatory filing. Pershing Square Capital Management, the investment vehicle of activist shareholder Bill Ackman, informed Valeant that PS Fund 1 had sold all of its 2.2 million shares in Allergan allocated to Valeant USA.

Valeant said PS Fund 1 is a shell fund Pershing Square set up with Valeant to act as a joint acquisition vehicle. Together the two parties had held a 9.7% stake in Allergan.

Ireland-based drugmaker Actavis offered $219 per share in cash and stock for a total acquisition price of $66 billion, topping the last Pershing Square-Valeant bid by as much as $12 billion.

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.